Urogen Pharma (URGN) Competitors

Lantheus (NASDAQ:LNTH) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Does the media prefer LNTH or URGN?

In the previous week, Lantheus had 3 more articles in the media than Urogen Pharma. MarketBeat recorded 23 mentions for Lantheus and 20 mentions for Urogen Pharma. Lantheus' average media sentiment score of 0.38 beat Urogen Pharma's score of -0.10 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	6 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral

Is LNTH or URGN more profitable?

Lantheus has a net margin of 17.82% compared to Urogen Pharma's net margin of -164.44%. Lantheus' return on equity of 34.06% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.82%	34.06%	19.10%
Urogen Pharma	-164.44%	-97,487.15%	-59.38%

Do analysts recommend LNTH or URGN?

Lantheus currently has a consensus target price of $105.50, suggesting a potential upside of 93.68%. Urogen Pharma has a consensus target price of $31.43, suggesting a potential upside of 56.52%. Given Lantheus' higher possible upside, analysts clearly believe Lantheus is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Urogen Pharma	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has better earnings and valuation, LNTH or URGN?

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.53B	2.41	$312.44M	$3.76	14.49
Urogen Pharma	$90.40M	10.28	-$126.87M	-$3.32	-6.05

Which has more volatility and risk, LNTH or URGN?

Lantheus has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Do insiders & institutionals hold more shares of LNTH or URGN?

99.1% of Lantheus shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 1.5% of Lantheus shares are held by company insiders. Comparatively, 4.7% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Lantheus beats Urogen Pharma on 11 of the 17 factors compared between the two stocks.